Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Inclusion Criteria:

• Age: 18 to 70 years old; Karnofsky (KPS) ≥ 60 points; Expected survival periodexceeding 6 months;

• Previously received allogeneic hematopoietic stem cell transplantation;

• According to NIH standards, the clinical diagnosis is moderate to severe cGVHD；

• Previously received systematic treatment for cGVHD with 2-5 lines;

• Stable dosage of corticosteroids and other immunosuppressants received within 2weeks prior to screening;

• The main organ functions well;

• Starting from Day 1 after enrollment in the control group of this study,participants must receive one of the drugs specified in the study protocol;

• Female participants of childbearing age should agree to use contraceptive measures (such as intrauterine devices, birth control pills, or condoms) during the studyperiod and for 6 months after the end of the study; Serum pregnancy test negativewithin 7 days prior to enrollment in the study, and must be a non lactating subject;Male participants should agree to use contraceptive measures during the study periodand within 6 months after the end of the study period;

• Subjects voluntarily joined this study, signed informed consent, and had goodcompliance.

Exclusion Criteria:

• Has experienced or currently suffers from other malignant tumors within the past 3years;

• Known or suspected active aGVHD；

• Individuals with interstitial pneumonia, non infectious pneumonia, uncontrolledactive infections, or infections requiring systematic treatment within the first 7days of randomization, except for those deemed suitable for inclusion by theresearchers;

• The occurrence and progression of other underlying diseases include post transplantlymphoid tissue proliferative diseases and recurrence of primary malignanthematological diseases;

• Random failure of allogeneic hematopoietic stem cell transplantation within thefirst 6 months or having received 2 allogeneic hematopoietic stem cell transplantsin the past;

• Used JAK inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, etc. within thefirst 2 weeks of randomization;

• There are multiple factors that can affect oral medication, such as inability toswallow, intestinal obstruction, etc;

• Individuals with a history of abuse of psychotropic drugs who are unable to quit orhave mental disorders;

• Subjects with any severe and/or uncontrolled illnesses;

• Individuals who are allergic to research drugs or their components;

• Participated in other clinical trials within the first 4 weeks of randomization;

• According to the researcher's judgment, there are accompanying diseases thatseriously endanger the safety of the subjects or affect the completion of the study,or subjects who are deemed unsuitable for inclusion due to other reasons.